Closed loop system for diabetes (Artificial Pancreas)
OHSU # 1521
“Analyte sensing and response system for a closed loop “Artificial Pancreas” system”
A family of 4 issued patents and one pending patent application describing the use of an implantable sensor and methods to calculate delivery of glucagon.
US 5,711,861 Device for monitoring changes in analyte concentration A fully-implantable, subcutaneous disk-shaped glucose sensor with multiple sensing electrodes to improve sensor accuracy and methods of calculating glucose values from electrical current measurements.
US 6,212,416 Device for monitoring changes in analyte concentration method to avoid interference from oxidizable interferents such as acetaminophen and ascorbic acid. Uses a subtraction system where some electrodes are coated with glucose oxidase; when one signal is subtracted from the other, the difference yields the pure glucose signal independent of interfering compounds. Adds an inhibitor of fibrosis. CIP of 5,711,861.
US 7,433,727 Implantable device for monitoring changes in analyte concentration Method to calculate glucose values (ZMAD) when there are multiple signals coming in from many redundant sensors. ZMAD uses a Z-statistic, median of absolute deviations, and leads to increased accuracy vs the use of a single sensing unit. DIV of 5,711,861.
US 8,114,023 Analyte sensing and response system Use of an algorithm that allows effective closed loop (artificial pancreas) control of glucose in persons with diabetes. This method is known as the fading memory proportional derivative control method.
US-2011-0054391- Analyte sensing and response system Use of a bihormonal approach for the closed loop control of diabetes. Includes the use of glucagon and method of “front-loaded” delivery of glucagon. CIP to 8,114,023.
For more information, contact:
Senior Technology Development Manager